The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

The Ministry of Food and Drug Safety announced on the 20th that it has approved the severe myasthenia gravis treatment "Vyvgart" (active ingredient efgartigimod alpha) from Belgian pharmaceutical ...

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Mestinon (pyridostigmine) is a prescription drug used to treat myasthenia gravis. This drug can interact with other medications. For example, Mestinon can interact with corticosteroids and ...

Some drugs inhibit neuromuscular signal transmission ... No writing assistance was utilized in the production of this manuscript. Myasthenia gravis (MG) should be subgrouped into early-onset ...

Myasthenia gravis (MG) should be classified according ... whereas rituximab is a promising second choice drug for severe generalized MG. Thymectomy is recommended for early-onset, generalized ...

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...